Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease

References

• Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455–532.
   PubMed Web of Science ®Google Scholar
• Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Biochim Biophys Acta. 2000;1502:172–187.
   PubMed Web of Science ®Google Scholar
• Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA. 2009;106:4012–4017.
   PubMed Web of Science ®Google Scholar
• Khan SS, Bloom GS. Tau: the center of a signaling nexus in Alzheimer’s disease. Front Neurosci. 2016;10:31.
   PubMed Web of Science ®Google Scholar
• Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer’s disease: synapses gone cold. Mol Neurodegener. 2011;6:63.
   PubMed Web of Science ®Google Scholar
• Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–580.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298:789–791.
   PubMed Web of Science ®Google Scholar
• Crimins JL, Pooler A, Polydoro M, et al. The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res Rev. 2013;12:757–763.
   PubMed Web of Science ®Google Scholar
• Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron. 2014;82:756–771.
   PubMed Web of Science ®Google Scholar
• Santos AN, Ewers M, Minthon L, et al. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer’s disease. J Alzheimers Dis. 2012;29:171–176.
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009;110:1129–1134.
   PubMed Web of Science ®Google Scholar
• Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology. 2001;56:127–129.
   PubMed Web of Science ®Google Scholar
• Scheff SW, Price DA, Schmitt FA, et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501–1508.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
   PubMed Web of Science ®Google Scholar
• Tsai J, Grutzendler J, Duff K, et al. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci. 2004;7:1181–1183.
   PubMed Web of Science ®Google Scholar
• Spires TL, Hannan AJ. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. FEBS J. 2005;272:2347–2361.
   PubMed Web of Science ®Google Scholar
• Hartley DM, Walsh DM, Ye CP, et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999;19:8876–8884.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448–6453.
   PubMed Web of Science ®Google Scholar
• Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837–842.
   PubMed Web of Science ®Google Scholar
• Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–39.
   PubMed Web of Science ®Google Scholar
• Townsend M, Shankar GM, Mehta T, et al. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477–492.
   PubMed Web of Science ®Google Scholar
• Li S, Hong S, Shepardson NE, et al. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788–801.
   PubMed Web of Science ®Google Scholar
• Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812–818.
   PubMed Web of Science ®Google Scholar
• Giannakopoulos P, Herrmann FR, Bussière T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60:1495–1500.
   PubMed Web of Science ®Google Scholar
• Kopeikina KJ, Hyman BT, Spires-Jones TL. Soluble forms of tau are toxic in Alzheimer’s disease. Transl Neurosci. 2012;3:223–233.
   PubMed Web of Science ®Google Scholar
• Tai HC, Serrano-Pozo A, Hashimoto T, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181:1426–1435.
   PubMed Web of Science ®Google Scholar
• Bliss TV, Collingridge GL, Morris RG. Synaptic plasticity in health and disease: introduction and overview. Philos Trans R Soc Lond B Biol Sci. 2013;369:20130129.
   PubMed Web of Science ®Google Scholar
• Benfenati F. Synaptic plasticity and the neurobiology of learning and memory. Acta Biomed. 2007;78:58–66.
   PubMedGoogle Scholar
• Dudai Y, Morris RG. Memorable trends. Neuron. 2013;80:742–750.
   PubMed Web of Science ®Google Scholar
• Díez-Guerra FJ. Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life. 2010;62:597–606.
   PubMed Web of Science ®Google Scholar
• Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci. 2002;3:175–190.
   PubMed Web of Science ®Google Scholar
• Mulkey RM, Endo S, Shenolikar S, et al. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486–488.
   PubMed Web of Science ®Google Scholar
• Zhong L, Gerges NZ. Neurogranin and synaptic plasticity balance. Commun Integr Biol. 2010;3:340–342.
   PubMedGoogle Scholar
• Gerendasy DD, Sutcliffe JG. RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol. 1997;15:131–163.
   PubMed Web of Science ®Google Scholar
• Gerendasy DD, Herron SR, Wong KK, et al. Rapid purification, site-directed mutagenesis, and initial characterization of recombinant RC3/neurogranin. J Mol Neurosci. 1994;5:133–148.
   PubMed Web of Science ®Google Scholar
• Baudier J, Deloulme JC, Van Dorsselaer A, et al. Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem. 1991;266:229–237.
   PubMed Web of Science ®Google Scholar
• Huang KP, Huang FL, Chen HC. Characterization of a 7.5-kDa protein kinase C substrate (RC3 protein, neurogranin) from rat brain. Arch Biochem Biophys. 1993;305:570–580.
   PubMed Web of Science ®Google Scholar
• Ran X, Miao HH, Sheu FS, et al. Structural and dynamic characterization of a neuron-specific protein kinase C substrate, neurogranin. Biochemistry. 2003;42:5143–5150.
   PubMed Web of Science ®Google Scholar
• Gerendasy DD, Herron SR, Jennings PA, et al. Calmodulin stabilizes an amphiphilic alpha-helix within RC3/neurogranin and GAP-43/neuromodulin only when Ca2+ is absent. J Biol Chem. 1995;270:6741–6750.
   PubMed Web of Science ®Google Scholar
• Represa A, Deloulme JC, Sensenbrenner M, et al. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990;10:3782–3792.
   PubMed Web of Science ®Google Scholar
• Singec I, Knoth R, Ditter M, et al. Neurogranin is expressed by principal cells but not interneurons in the rodent and monkey neocortex and hippocampus. J Comp Neurol. 2004;479:30–42.
   PubMed Web of Science ®Google Scholar
• Guadaño-Ferraz A, Viñuela A, Oeding G, et al. RC3/neurogranin is expressed in pyramidal neurons of motor and somatosensory cortex in normal and denervated monkeys. J Comp Neurol. 2005;493:554–570.
   PubMed Web of Science ®Google Scholar
• Watson JB, Sutcliffe JG, Fisher RS. Localization of the protein kinase C phosphorylation/calmodulin-binding substrate RC3 in dendritic spines of neostriatal neurons. Proc Natl Acad Sci USA. 1992;89:8581–8585.
   PubMed Web of Science ®Google Scholar
• Houben MP, Lankhorst AJ, van Dalen JJ, et al. Pre- and postsynaptic localization of RC3/neurogranin in the adult rat spinal cord: an immunohistochemical study. J Neurosci Res. 2000;59:750–759.
   PubMed Web of Science ®Google Scholar
• Ramakers GM, Gerendasy DD, de Graan PN. Substrate phosphorylation in the protein kinase Cgamma knockout mouse. J Biol Chem. 1999;274:1873–1874.
   PubMed Web of Science ®Google Scholar
• Bähler M, Rhoads A. Calmodulin signaling via the IQ motif. FEBS Lett. 2002;513:107–113.
   PubMed Web of Science ®Google Scholar
• Yu W, Lu B. Synapses and dendritic spines as pathogenic targets in Alzheimer’s disease. Neural Plast. 2012;2012:247150.
   PubMed Web of Science ®Google Scholar
• Mahoney CW, Pak JH, Huang KP. Nitric oxide modification of rat brain neurogranin. Identification of the cysteine residues involved in intramolecular disulfide bridge formation using site-directed mutagenesis. J Biol Chem. 1996;271:28798–28804.
   PubMed Web of Science ®Google Scholar
• Huang KP, Huang FL, Li J, et al. Calcium-sensitive interaction between calmodulin and modified forms of rat brain neurogranin/RC3. Biochemistry. 2000;39:7291–7299.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Putkey JA, Waxham MN. Neurogranin controls the spatiotemporal pattern of postsynaptic Ca2+/CaM signaling. Biophys J. 2007;93:3848–3859.
   PubMed Web of Science ®Google Scholar
• Zhong L, Cherry T, Bies CE, et al. Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J. 2009;28:3027–3039.
   PubMed Web of Science ®Google Scholar
• Hayashi Y. Long-term potentiation: two pathways meet at neurogranin. EMBO J. 2009;28:2859–2860.
   PubMed Web of Science ®Google Scholar
• Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer’s disease. Int Psychogeriatr. 1998;10:11–23.
   PubMedGoogle Scholar
• Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005;7:103–117.
   PubMed Web of Science ®Google Scholar
• Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis. 1999;20:431–437.
   PubMed Web of Science ®Google Scholar
• Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res. 2010;1362:13–22.
   PubMed Web of Science ®Google Scholar
• Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement. 2015;11:1180–1190.
   PubMed Web of Science ®Google Scholar
• Kvartsberg H, Portelius E, Andreasson U, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls. Alzheimers Res Ther. 2015;7:40.
   PubMed Web of Science ®Google Scholar
• De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer’s disease. Alzheimers Dement. 2015;11:1461–1469.
   PubMed Web of Science ®Google Scholar
• Portelius E, Zetterberg H, Skillbäck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain. 2015;138:3373–3385.
   PubMed Web of Science ®Google Scholar
• Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72:1275–1280.
   PubMed Web of Science ®Google Scholar
• Scheff SW, Price DA, Ansari MA, et al. Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer’s disease. J Alzheimers Dis. 2015;43:1073–1090.
   PubMed Web of Science ®Google Scholar
• Ingelsson M, Fukumoto H, Newell KL, et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925–931.
   PubMed Web of Science ®Google Scholar
• Blennow K, Bogdanovic N, Alafuzoff I, et al. Synaptic pathology in Alzheimer’s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996;103:603–618.
   PubMed Web of Science ®Google Scholar
• Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology. 2009;73:1353–1358.
   PubMed Web of Science ®Google Scholar
• Buerger K, Otto M, Teipel SJ, et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging. 2006;27:10–15.
   PubMed Web of Science ®Google Scholar
• Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 2003;8:343–347.
   PubMed Web of Science ®Google Scholar
• Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86:829–835.
   PubMed Web of Science ®Google Scholar
• Janelidze S, Hertze J, Zetterberg H, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol. 2015;3:12–20.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Kvartsberg H, Portelius E, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther. 2015;7:74.
   PubMed Web of Science ®Google Scholar
• Rapoport SI. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 1999;249:46–55.
   PubMed Web of Science ®Google Scholar
• Arendt T. Synaptic degeneration in Alzheimer’s disease. Acta Neuropathol. 2009;118:167–179.
   PubMed Web of Science ®Google Scholar
• Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging. 1990;11:29–37.
   PubMed Web of Science ®Google Scholar
• Scheff SW, Price DA, Schmitt FA, et al. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging. 2006;27:1372–1384.
   PubMed Web of Science ®Google Scholar
• Arendt T. Alzheimer’s disease as a disorder of mechanisms underlying structural brain self-organization. Commentary. Neuroscience. 2001;102:723–765.
   PubMed Web of Science ®Google Scholar
• Arendt T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity. Progr Neurobiol. 2003;71:83–248.
   PubMed Web of Science ®Google Scholar
• Sorg C, Riedl V, Mühlau M, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer’s disease. Proc Natl Acad Sci USA. 2007;104:18760–18765.
   PubMed Web of Science ®Google Scholar
• Wang L, Zang Y, He Y, et al. Changes in hippocampal connectivity in the early stages of Alzheimer’s disease: evidence from resting state fMRI. Neuroimage. 2006;31:496–504.
   PubMed Web of Science ®Google Scholar
• Bai F, Zhang Z, Watson DR, et al. Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment. Biol Psychiatry. 2009;65:951–958.
   PubMed Web of Science ®Google Scholar
• Johnson SC, Schmitz TW, Moritz CH, et al. Activation of brain regions vulnerable to Alzheimer’s disease: the effect of mild cognitive impairment. Neurobiol Aging. 2006;27:1604–1612.
   PubMed Web of Science ®Google Scholar
• Supekar K, Menon V, Rubin D, et al. Network analysis of intrinsic functional brain connectivity in Alzheimer’s disease. PLoS Comput Biol. 2008;4:e1000100.
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol. 1990;27:457–464.
   PubMed Web of Science ®Google Scholar
• Davies CA, Mann DM, Sumpter PQ, et al. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. J Neurol Sci. 1987;78:151–164.
   PubMed Web of Science ®Google Scholar
• Bertoni-Freddari C, Fattoretti P, Casoli T, et al. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer’s type. Anal Quant Cytol Histol. 1996;18:209–213.
   PubMed Web of Science ®Google Scholar
• Masliah E, Terry RD, Alford M, et al. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer’s disease. Am J Pathol. 1991;138:235–246.
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Albright T, et al. Immunoelectron microscopic study of synaptic pathology in Alzheimer’s disease. Acta Neuropathol. 1991;81:428–433.
   PubMed Web of Science ®Google Scholar
• Sze CI, Troncoso JC, Kawas C, et al. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:933–944.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Blennow K. Neurogranin levels in cerebrospinal fluid: a new addition to the Alzheimer disease diagnostic toolbox. JAMA Neurol. 2015;72:1237–1238.
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging. 2013;17:54–63.
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci. 2015;9:345.
   PubMed Web of Science ®Google Scholar
• Lista S, Khachaturian ZS, Rujescu D, et al. Application of systems theory in longitudinal studies on the origin and progression of Alzheimer’s disease. Methods Mol Biol. 2016;1303:49–67.
   PubMedGoogle Scholar
• Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 2012;8:312–336.
   PubMed Web of Science ®Google Scholar
• Montine TJ, Montine KS. Precision medicine: clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases. J Exp Med. 2015;212:601–605.
   PubMed Web of Science ®Google Scholar
• Reitz C. Toward precision medicine in Alzheimer’s disease. Ann Transl Med. 2016;4:107.
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–795.
   PubMed Web of Science ®Google Scholar